Just sat for my CFA Level 2 exam.
Was busy preparing for the exam for the past few days, and so couldn't focus on Equity Research and content creation.
Now that my exam is over, a lot of company analysis posts and videos from my side will come to your feed.
I plan to first analyze NBFCs, and also focus on sharing Portfolio Management insights from now on.
I will share my detailed plans for the next few days by today night.
3
7
257
Jeena Sikho's Q2 results are also not good.
#JSLL
Jeena Sikho is a reminder to never go against the numbers.
Q4 FY26 was the first quarter of moderate growth.
Q1 FY27 was the second quarter of moderate growth.
----
What was the first mistake investors did with Jeena Sikho?
Company's management gave a long term guidance of growing their revenue and PAT at a good rate.
Investors believed that one or two quarters of moderate growth does not change the story of the company.
So they stayed invested.
But, Guidance is what management and investors see.
Execution is what market sees.
So we need to put a greater importance on execution over guidance.
-----
Second mistake?
Investors became emotional.
They never took the decision of trimming or exiting their allocation in the company because they never listened to their mind.
They believed that aaj nahi to kal stock ka comeback to hoga hi.
------
Starting today, companies will start reporting Q2 FY27 results.
Any of our portfolio company may report bad numbers.
Remember to not do these same mistakes again.
1
2
467
Good number from Kwality Pharma yet again.
Growth achieved across all the parameters.
Revenue grew by over 60%, and EBITDA margin stretched by 400 bps to 27%.
PAT has grown faster than revenue (105%).
Management has also raised their FY27 revenue and PAT guidance.
They now guide for a 43% growth in revenue in FY27 over FY26, and a PAT growth of over 80%.
Kwality Pharmaceuticals : Solid Q1 FY27 numbers, along with guidance hike.
Let's analyze the company in detail.
Company's Business Model :
Kwality Pharma purchases special medicine ingredients, known as APIs and then converts these APIs into final usable medicines like capsules, syrups, injections, etc.
The medicines they manufacture are used to cure ordinary health problems, protect from infections, oncology medicines, etc. They also share the formula of medicines to other companies, and collect fees from them.
Their total revenue comes from around 2 segments : Out-licensing (90%), and CDMO (10%).
Q1 FY27 Results :
~Revenue grew by 46% YoY to 162 cr.
~EBITDA margins expanded by 300 bps YoY to 25%
~PAT grew more than 2x to 26 cr
~Despite Q1 usually being a bit weaker than Q4, company has recorded good growth QoQ across all parameters
~This growth is driven by expansion into newer geographies, continued R&D and strengthening their footprint
Capex details :
~They are working on adding a new product - named Hormones. The commercial production of this product is expected to begin from H2 FY26.
~Around 65 cr of capex is expected to be incurred in this plant, with a potential of contributing Rs 150 cr to the top-line.
~They are also doing a multi-year capex in their biologics facility, where they will be adding capacities.
~Their FY29 revenue guidance of 1000 cr excludes contribution from both these manufacturing plants, thereby the chances of guidance hike has increased.
FY27 guidance :
~They now guide for 39% revenue growth vs 29% growth guidance earlier.
~EBITDA margin is expected to be in the range of 27-28%.
~PAT margin is expected to be around 15.5%.
US-Iran war ka impact ab dekhne ko mil raha hai.
Many companies are reporting margin pressure in Q2 FY27.
Another quarter of margin pressure will confirm that the impact of US-Iran war is real.
2
255
India Shelter Finance's guidance has been lowered in Q2 FY27.
After a weak Q1, Q2 has been decent.
AUM grew by 23% in Q2 FY27, and they were earlier guiding for 25-30% growth in AUM in FY27, which has now been changed to 25-27%.
After Q1 results were weak, those who did not trim their position/exit and were waiting that Q2 will be good are now suffering.
Another reason to trim your position in the company whose results are not up to the mark.
Don't wait for next quarter's performance.
Key takeaways from India Shelter's Q1 FY27 concall :
[Full dhulai of the management today]
1. Company has changed the accounting method of recording disbursements. Earlier, disbursements were recorded at cheque handover (booking). Now the disbursements are recorded upon cheque clearance.
2. Management is confident of achieving 20% disbursements growth in FY27, even after the changes in accounting method.
3. Management said that the worsening of asset quality was due to seasonality and monthly fluctuations. The same problem happened in Q3 of the previous year also.
4. GNPA in Q2 FY27 is expected to remain similar to Q1 FY27. CE and 30+ DPD may see some minute improvements. Major improvement in all parameters will be seen from Q3 onwards.
5. Asset quality worsened because of the stress among the smaller ticket-size customer segment. They have experienced temporary financial pressure over the recent quarters.
6. Management says that if the change in accounting policy had not happened, AUM and disbursements would have shown more growth.
7. Company's current credit cost is 0.5%, and they say that despite of all these concerns in asset quality, they will be able to maintain their 40-50 bps credit cost guidance for FY27.
8. Earlier, company used to grow their AUM by 30-35%, but now they have reduced their guidance. Management states that they don't want to chase 30-35% growth in this period of macro/seasonal stress. They say that they are okay with 25-30% growth, considering that the profitability is improved, and risk is managed properly.
9. After adjusting for accounting changes, company's disbursements grew by only 18%, far less than their competitors. Management says not to look just on one quarter's performance and they are still confident of delivering 25-30% AUM growth for the full year.
10. They guided for around 50 new branch addition in FY27. However, they have added none in Q1, and are expected to expand branches from Q2 onwards.
Clearly a disappointing quarter from India Shelter. Let's see how things unfold in upcoming quarters
[Read the discussion between the management and the participants Umang Shah, Mayank Mistry. It was one hell of a discussion where they have raised tough questions against the management. In fact, one of the participant directly said that the AUM growth rate guidance has fallen from 30-35% to now 25-30% and he expects that this will fall further🤣]
2
11
799
TD Power Systems is now down 35% from its ATH.
Company's performance in Q1 was too good, and its Q2 results will be out on 12 Nov.
According to me, as of current conditions, it looks like a steal deal.
Key takeaways from the Q1 FY27 con call of TD Power Systems :
1. Company achieved its higher ever quarterly revenue of Rs 640 cr. It grew by 72% YoY and 9% QoQ, backed by solid execution of their order book backlog.
2. Management mentions that they have sufficient capacity for achieving good revenue in FY28. Now they are planning capex to increase revenue potential for FY29 and FY30.
3. This year is expected to be one of the best year for the company in terms of hydro segment. Some high value orders are expected to be received in this segment in Q2.
4. Management revised their FY27 revenue guidance upwards from 2400 cr to 2600 cr, with a small chance of beating their new guidance also.
5. Management is expecting around 700 cr of orders per quarter, implying for a 2800 cr order inflow for FY27.
6. Expected capex for FY27 is Rs 50 cr. They are also doing debottlenecking capex, which will help them achieve at least Rs 3200 cr of revenue in FY28.
7. There is a bit of delay in the completion of the orders which are related to data center.
8. Company does not have any major client additions at the moment, but they have a couple of smaller clients additions. Management informs that some of the major clients are already working with them, and now they aim to further deepen their relationship with them.
9. Around 3.5 million Euro worth of orders will be executed in their Turkey plant.
10. Service business contributes to around 5-6% of the total revenue.
11. Working capital is expected to remain in the same position as it is currently.
12. Other current liabilities increased this quarter due to the increase in customer advances.
13. FY28 revenue guidance is Rs 3200 cr. This may go a bit up or down depending on the market situation at that time.
Before a company's results were announced, suppose it was trading at price X.
Then its results came, results were very good, management raised/maintained their guidance, stock went up and the next day it was trading at a higher price.
After few days, i.e. today, due to bearish market sentiment, the same stock's price fell down and is now trading below price X.
Consider yourself very lucky because you can now buy the same stock, with higher conviction at a lower price than it was trading before results were announced.
Now the important point comes that if one is fully invested and has no cash, how to take advantage of this opportunity.
The answer is capital rotation.
Build a watchlist of 30-40 companies which have delivered great results and their future also looks bright.
If you hold any of these companies in your portfolio, and they are trading at an ATH or near its ATH, book some profits and reinvestment the amount in those companies from the watchlist which are trading 20-30% below their ATH.
You have to sell the stock at its ATH not because it is a bad company, but you have much better opportunity available in the market. Since one has limited capital only, he can try following this technique to exploit the juicy opportunities available in the market.
8
344
KSH International Q2 FY27 Results & Concall Highlights:
1. Revenue grew by 85% YoY and 13% QoQ to 1320 cr, and EBITDA margin also expanded YoY and QoQ, and now stands at 6.8%.
2. PAT grew at a lesser rate than revenue (62%), primarily because of higher Finance costs. Though the value of debt fell down YoY, finance costs still increased because of higher bank fees and supplier financing charges.
3. Current capacity stands at 58,000 metric tons. They were doing capex and earlier guided that they would have 59,000 metric tons capacity by Q4 FY27, but company has added 96% of the planned expansion capacity six months ahead of schedule. Current utilization level stands at 76%.
4. They have also announced further expansion plans. This capacity of 58,000 MTs will be expanded to 72,000 MTs by Q1 FY29. Rs 185 cr of capex is planned for this expansion.
5. Company has two product segments: Specialized magnet winding wires (high margin segment) and Standard magnet winding wires (low margin segment). Management is planning to increase the contribution from the higher margin segment. 75% of the total revenue comes from Specialized magnet winding wires and 25% comes from Standard magnet winding wires.
6. Revenue witnessed good growth this quarter because of increased contribution from higher margin segment, higher exports, and higher utilization levels.
7. KSH is a make-to-order company, which means they manufacture products only after they receive orders from their clients. This gives them the ability to pass on any rise in raw material prices directly to the customers.
8. EBITDA per ton grew by 55% YoY to over Rs 1,00,000. However, management states that Rs 85,000 EBITDA per ton is a more sustainable number and there will be quarters when the actual number will exceed and some quarter when the actual number will be below this sustainable number.
9. Regarding exports to the Middle East, transit times and transport costs have increased significantly.
10. Exports currently contribute to 32% of the total revenue (vs 26% QoQ). Their target is to take this number to 40%.
Syrma SGS Technology Ltd: Management informs that the company witnessed potential supply chain constraints due to which margins fell QoQ.
These supply chain constraints are expected to ease only between April and June 2027 (Q1 FY28).
Cost of materials also increased this quarter because of which margins fell down.
Though management has increased their FY27 revenue guidance to 40-45%(which is obviously conservative), they have reduced their margins guidance for FY27.
Management was earlier expecting EBITDA margins of 10.5-11% for FY27, which has now been lowered to 10-10.5%.
Suryoday SFB Q2 FY27 Results & Concall Insights:
AUM grew by a record 35% YoY to 15,000 cr, at par with their guidance of 30-35%, and Disbursements grew by 27% YoY.
Share of Inclusive Finance (Unsecured book) fell from 45% to 41% YoY, and Retail Assets (Secured Book) has risen to 59%.
Major improvement was seen in asset quality this quarter as GNPA & NNPA number halved on a YoY basis. Collection Efficiency also improved from 85% to 94% YoY. Though these numbers have improved, there is still significant room left for asset quality to improve.
NIMs remained stable on a YoY basis, and PAT grew by 150% YoY.
Though CASA ratio fell by 100 bps on a YoY basis, Cost of Funds improved from 7.7% to 7.4% YoY.
As of now, no negative impact has been seen in the asset quality of the unsecured MFI book due to drought situations. However, due to precautionary care, management has decided to not add any new customers from drought-hit areas for the remainder of the year.
Company's portfolio is predominantly concentrated in semi-urban areas rather than rural areas, thereby protecting the bank from any immediate agriculture related impact in the rural areas. However, agricultural shocks have a lagged impact, so it will be important to see how Q3 is executed.
Disbursements which happened in previous years are covered under the CGFMU scheme, which is a kind of government insurance scheme. However, disbursements of FY27 so far have not been covered as the renewal window has not yet opened.
There has been some rise in PAR 30-90 in the unsecured book. Management informed that this segment naturally experiences cash flow fluctuations, and borrowers keep entering and exiting this bucket. The real danger mark is only when it crosses 90+ DPD, which has improved for unsecured book, but risen for secured book.
PAR 90 has increased for secured book, which is primarily due to one or two large transactions slipping into this 30+ or 90+ bucket. Management expressed full confidence in recovering this stuck amount.
6
543
Capri Global Capital Q2 FY27 Results & Concall Analysis:
AUM grew by 62% YoY to over 44,000 cr. PAT grew by an even faster rate at 77%.
Talking about the segment wise AUM growth, gold loan grew the fastest, by over 100% and now contributes to approx. 50% of the total AUM. MSME and Housing loans also witnessed decent growth this quarter.
Disbursements grew by 50% YoY to 13,300 cr. NIM witnessed a slight growth on a YoY basis and stood at 9.6%.
Asset quality in the gold loan segment worsened on a QoQ basis. GNPA rose from 0.3% to 1.3% in just one quarter. This is because the company introduced shorter repayment cycles from this quarter. The borrower was earlier adopted to paying EMIs annually and so they could not adjust to this new cycle leading to a spike in NPAs.
But now management has discontinued this shorter repayment cycles, and NPAs will return to their earlier levels from next quarter.
But asset quality in the Construction Finance segment improved a lot on a QoQ basis. It transitioned from 0.7% to 0%, leading to overall GNPA rising by a low amount.
Drought situation has arisen in some states of the country. Only gold loan segment has suffered some stress because of the drought. Other segments have not witnessed any effect.
Other segments like MSME, Housing Finance have stable asset quality and are doing good in terms of growth and disbursements.
As part of branch expansion journey, company added 176 branches this quarter. Branch expansion contributed significantly to helping Capri Global grow its AUM at such a huge rate. They will be adding around 600 branches in FY27, 500 of them will be of gold loans.
AUM per branch has come down this quarter, and this is primarily because of the rapid branch addition.
Credit cost was around 0.8%, and management guides it to remain between 0.6 to 0.9% in this year.
Management is retaining their FY27 AUM guidance of 50,000 cr and they expect PAT to be around 1,600 cr.
FY28 guidance:
AUM - 65,000 cr
RoAE - 19 to 21%
RoAA - 4.2 to 4.7%
1
11
493
Shanti Gold is down 30% from its All Time High (ATH).
Right time to analyse the company.
#SHANTIGOLD
Shanti Gold is adding a lot of capacity in the business. After their newly commissioned Marol plant, they are now working on setting up a manufacturing plant in Jaipur.
This plant in Jaipur is expected to be operational from November or December.
Both these new plants will around 5,200 kg p.a. of capacity to the business, taking the total capacity to 7,900 kg p.a. , up from earlier capacity of 2,700 kg p.a.
A good utilization level of these new plants will contribute significantly to the top-line.
For FY27, management maintains their guidance of 30-40% volume growth and 50-60% value growth, contributing to a total top-line growth of around 100%.
2
17
1,558
Senores Pharma Q2 FY27 Results & Concall Analysis:
Revenue grew by 25% YoY to Rs 192 cr and EBITDA grew by 38% YoY. EBITDA margins also expanded by 300 bps YoY to 30%.
Despite PAT(22%) growing at a lesser rate than revenue(25%), management remains confident of achieving 50-60% PAT growth this quarter.
Their two subsidiaries, Zoraya and Amerisyn will start contributing to revenue from H2 onwards. Because they were in the setup stage till now, they were incurring huge costs without contributing to the top-line, dragging profitability downwards.
A more meaningful ramp up of both these subsidiaries is expected from FY28 onwards, wherein we can expect that they contribute good numbers to revenue and profits. They are confident of growing revenue by 25% for the next 2-3 years.
Company's approved ANDA approvals nearly doubled YoY, and it stands at 64 by the end of this quarter. 23 of these 64 ANDAs have been commercialized. The remaining 41 ANDAs are expected to commercialize within the next 6-8 quarters.
Talking about the Emerging Market segment, their EBITDA margins fell down this quarter because of higher revenue contribution from lower margin product. It is again expected to normalize from Q3 onwards. And margins of Regulated market segment is also expected to expand sequentially by 1-2 percentage points in the future.
H2 FY27 will be better than H1 FY27 for the company.
Their Apnar facility is already running at peak utilization levels. They are currently undergoing capex in this plant, which is expected to complete by Q4 FY27. This plant is expected to contribute 100 cr to the top-line this year.
FY27 guidance:
30-40% revenue growth
Atleast 30% EBITDA margin
50-60% growth in PAT
Yasho Industries
Some things in which we need to be careful after this quarter.
Management has decreased EBITDA margin guidance from 24% earlier to 20-21% now, which is a huge cut.
Rise in cost of raw materials has led to a bit of fall in margins. Management said that they will not be able to fully pass on these costs to customers, which leads us to believe that the company has less pricing power.
Freight costs was another reason why margins fell, and the management says that they can't comment on whether the freight cost may come down in upcoming quarters or not.
Hence, I can sense some challenges in maintaining even this 21% margin level also. Management commentary was very cautious this time.
Apart from this, the new capex which they are doing will be live from Q4 FY28 or beginning of FY29, so a lot of time until capacities get added.
Though company's top-line grew by 90%, and their future revenue guidance is good, but profitability and margins is still something we need to be cautious on.
As of now, there are other companies in the chemical industry which are doing good. I would focus on them rather than Yasho Industries.
Aeroflex Industries
Though change in depreciation method has led to inflated PAT this quarter, Adjusted PAT still grew by over 100% YoY.
Company's capex cycle is worth analyzing. Expansion in SS Flexible hoses has been completed and additional capacity is live from this quarter, and further expansion in SFN Skid Assemblies will also be live by Q3 FY27.
They have also announced a capex of Rs 200 cr to further expand these capacities, which will be live by Q4 FY28. This capex is for Hoses and Skids, and their capacities will become 1.5 to 2x of their current levels by Q4 FY28.
Earlier, management guided that they would reach at 30-35% utilization level of Skid Assemblies plant by the end of the year, but considering the robust demand scenario, they now project to touch 50% level by the end of the year. Flexible hose capacity is already running at 80% utilization level currently.
Guidance:
FY27 - 720 cr revenue (60% growth)
FY29 - 1000 cr revenue (Chances to beat this guidance are high)
FY30 - 1500 cr revenue, with the expanded capacity at peak utilization level
EBITDA margins are expected to be around 25% in the future.
Management has also announced the merger of Hyd-Air into Aeroflex, which is the company's wholly owned subsidiary. The reason behind the merger is that Aeroflex wants to use the existing facilities of Hyd Air to manufacture products which will be sold by Aeroflex. It would also reduce administrative and compliance related costs.
7
541
OneSource Specialty Pharma Ltd
Another great company in the pharma segment, with great guidance for future.
Company is involved in the research, development, and manufacturing of biological drug products in various injectable formats (such as GLP-1 pen injectors, Sterile injectables, Soft Gelatin Capsules, etc.). It also offers end-to-end CDMO services.
The products they manufacture are used to manage chronic conditions like diabetes and obesity, fight bacterial infections, etc.
Revenue grew by 37% YoY to Rs 500 cr, driven by higher capacity, new product launches, and growth across all product segments.
EBITDA margin expanded by 300 bps YoY to 32%, driven by operating leverage.
Company is guiding for Rs 3500 cr top-line and 40% EBITDA margin by FY28 (vs Rs 1400 cr revenue in FY26 with 24% EBITDA margins).
Company currently has one manufacturing site focused on scaling-up of Drug-Device Combination (GLP-1). Two phases of this plant is already operational, and the third one is expected to be operational by start of FY28. FY28 revenue growth will be primarily driven by this increased capacity.
Company is also undergoing a greenfield capex for their softgel product segment.
H2 FY27 will also be better than H1 FY27 for the business.
Its definitely one of the companies you must study.
One thing which I have realized happening in many companies growing at a high rate is that their Accounts Receivables are increasing.
Make sure that an increase in Accounts Receivables is not itself a red flag. Small companies generally have less bargaining power against their customers. So they have to sell goods on debt, they have no other option.
If debtors defaults, it becomes bad debts. Increase in bad debts is a red flag. If you see too much rise in this number, then become a bit cautious.
Apart from this, some companies have also reported an increase in Inventory days, which is also not a red flag by default. Considering the future demand scenario, some management increase their inventory levels before hand only, so that they do not miss on the execution part because of inventory.
Listen to what management says on this part. If they say that their products are not sold, that's why inventory levels have increased, then its a red flag. Otherwise if they have deliberately increased inventory levels, then chill..
7
449
Sky Gold raising funds is one of the best decisions they are taking.
Capital is required to grow at a high rate in the future - Either raise it via debt or equity.
Apart from this, fraud incident at a subsidiary is something we can consider a bit seriously. Because it has wiped out more than 7% of company's PAT this quarter.
If management clarifies that they are taking steps to prevent any such fraud in the future, then it's okay.
Kyuki fraud to ab ho gaya, what they can do is try to prevent any such frauds in the future.
No problems other than this, Q2 numbers were very good.
1
33
1,436
Sakar Healthcare
Change in product mix has played out really well. Higher contribution from oncology segment has led to improved growth this quarter also.
Oncology products have 2x margin than non-oncology products. More contribution from own brand exports to total revenue also contributes to higher profitability. Both of these are the reasons why company witnessed margin expansion this quarter.
There has been a significant expansion in the product portfolio of oncology segment, and the CDMO business segment also continued to gain momentum.
Management has continued to guide that the revenue contribution from oncology segment will be higher than non-oncology in the future because they have all the infrastructure available as well as demand is also there.
There is no impact of 30% margin cap by regulatory authorities on Sakar Healthcare.
Company's EBITDA margins will be touching 30% in the future.
Oncology plant is currently at 26% utilization level, and non-oncology plant is at 36%.
Total revenue this quarter was 87 cr (52% growth). Oncology segment contributed to 50 cr. Within oncology, exports was at 8.3 cr and remaining was domestic.
Management is looking for 100 cr revenue in next quarter itself and Q4 also.

















